Early and unrestricted access to high-efficacy disease-modifying therapies: a consensus to optimize benefits for people living with multiple sclerosis

Early intervention with high-efficacy disease-modifying therapy (HE DMT) may be the best strategy to delay irreversible neurological damage and progression of multiple sclerosis (MS). In European healthcare systems, however, patient access to HE DMTs in MS is often restricted to later stages of the...

Full description

Saved in:
Bibliographic Details
Published in:Journal of neurology 2022-03, Vol.269 (3), p.1670-1677
Main Authors: Filippi, Massimo, Danesi, Romano, Derfuss, Tobias, Duddy, Martin, Gallo, Paolo, Gold, Ralf, Havrdová, Eva Kubala, Kornek, Barbara, Saccà, Francesco, Tintoré, Mar, Weber, Jörg, Trojano, Maria
Format: Article
Language:English
Subjects:
Consensus
Health care
Humans
Medicine
Medicine & Public Health
Multiple sclerosis
Multiple Sclerosis - drug therapy
Neurology
Neuroradiology
Neurosciences
Patients
Resource allocation
Short
Short Commentary
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Early intervention with high-efficacy disease-modifying therapy (HE DMT) may be the best strategy to delay irreversible neurological damage and progression of multiple sclerosis (MS). In European healthcare systems, however, patient access to HE DMTs in MS is often restricted to later stages of the disease due to restrictions in reimbursement despite broader regulatory labels. Although not every patient should be treated with HE DMTs at the initial stages of the disease, early and unrestricted access to HE DMTs with a positive benefit–risk profile and a reasonable value proposition will provide the freedom of choice for an appropriate treatment based on a shared decision between expert physicians and patients. This will further optimize outcomes and facilitate efficient resource allocation and sustainability in healthcare systems and society.
ISSN:0340-5354
1432-1459
1432-1459
DOI:10.1007/s00415-021-10836-8